| __timestamp | BioMarin Pharmaceutical Inc. | Dr. Reddy's Laboratories Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 56369000000 |
| Thursday, January 1, 2015 | 152008000 | 62786000000 |
| Friday, January 1, 2016 | 209620000 | 62427000000 |
| Sunday, January 1, 2017 | 241786000 | 62453000000 |
| Monday, January 1, 2018 | 315264000 | 65724000000 |
| Tuesday, January 1, 2019 | 359466000 | 70421000000 |
| Wednesday, January 1, 2020 | 524272000 | 80591000000 |
| Friday, January 1, 2021 | 470515000 | 86645000000 |
| Saturday, January 1, 2022 | 483669000 | 100551000000 |
| Sunday, January 1, 2023 | 577065000 | 42907000000 |
| Monday, January 1, 2024 | 115557000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. This analysis delves into the cost of revenue for two major players: Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc., from 2014 to 2023.
Dr. Reddy's Laboratories has shown a consistent upward trend in its cost of revenue, peaking in 2024 with a staggering 115% increase from 2014. This growth reflects the company's expanding operations and market reach.
BioMarin, on the other hand, experienced a more volatile trajectory. Starting at a lower base, its cost of revenue surged by approximately 345% by 2023, indicating significant investment in product development and market expansion.
While Dr. Reddy's maintains a steady growth, BioMarin's fluctuations suggest a dynamic strategy, possibly driven by innovation and new product launches. Missing data for 2024 highlights the need for continuous monitoring.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Dr. Reddy's Laboratories Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Dr. Reddy's Laboratories Limited
Who Generates Higher Gross Profit? Dr. Reddy's Laboratories Limited or BioMarin Pharmaceutical Inc.
R&D Insights: How Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc. Allocate Funds
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.'s Expenses
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Iovance Biotherapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for BioMarin Pharmaceutical Inc. and Xencor, Inc.